$460 Million is the total value of Medicxi Ventures Management (Jersey) Ltd's 6 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
CNTA | CENTESSA PHARMACEUTICALS PLCsponsored ads | $299,329,000 | -24.8% | 17,923,892 | 0.0% | 65.12% | -8.7% | |
PHAT | PHATHOM PHARMACEUTICALS INC | $66,378,000 | -5.2% | 2,067,861 | 0.0% | 14.44% | +15.1% | |
PCVX | VAXCYTE INC | $47,885,000 | +12.7% | 1,887,478 | 0.0% | 10.42% | +36.8% | |
MRUS | MERUS N V | $35,200,000 | +4.4% | 1,600,000 | 0.0% | 7.66% | +26.7% | |
CMPI | CHECKMATE PHARMACEUTICALS IN | $5,962,000 | -33.4% | 1,501,716 | 0.0% | 1.30% | -19.1% | |
OBSV | OBSEVA SA | $4,883,000 | +2.6% | 1,570,000 | 0.0% | 1.06% | +24.5% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Francesco De Rubertis #1
- Kevin Stuart Johnson #2
- Michele Ollier #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-10
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
PHATHOM PHARMACEUTICALS INC | 16 | Q3 2023 | 69.8% |
MERUS N V | 16 | Q3 2023 | 25.3% |
VAXCYTE INC | 14 | Q3 2023 | 44.5% |
OBSEVA SA | 12 | Q3 2022 | 5.7% |
CENTESSA PHARMACEUTICALS PLC | 10 | Q3 2023 | 71.3% |
AURA BIOSCIENCES INC | 8 | Q3 2023 | 22.9% |
CHECKMATE PHARMACEUTICALS IN | 8 | Q2 2022 | 12.7% |
NEWAMSTERDAM PHARMA COMPANY | 4 | Q3 2023 | 11.4% |
SYNTHORX INC | 1 | Q4 2019 | 43.1% |
View Medicxi Ventures Management (Jersey) Ltd's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-04-15 |
13F-HR | 2024-02-01 |
3 | 2024-01-26 |
13F-HR | 2023-10-18 |
13F-HR | 2023-07-19 |
13F-HR | 2023-04-27 |
13F-HR | 2023-01-31 |
13F-HR | 2022-10-25 |
13F-HR/A | 2022-08-03 |
13F-HR | 2022-08-03 |
View Medicxi Ventures Management (Jersey) Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.